3D-185 is a selective fibroblast growth factor receptor (FGFR) inhibitor, which could significantly inhibit the activity of FGFR 1-3, and the safety and tolerability of 3D-185 monotherapy is being evaluated in a Phase 1a clinical trial in patients with advanced solid tumors who have failed standard therapies.
The fibroblast growth factor receptors (FGFRs) is an important tyrosine kinases receptor family. FGFR pathway abnormality is closely related to tumorigenesis and development of many cancer types. FGFR inhibitors have attracted much attention in the field of tumor therapy development recently, with potential to provide more therapy options for cancer patients. 3D-185 is a small molecule inhibitor selectively targeting FGFR1-3, and preclinical studies have demonstrated its anti-tumor activity. The high selectivity of 3D185 provides significant advantages in off-target toxicity reduction, selection of sensitive patients, and the design of combination therapy with other drugs.
Clinical Trial Progress
Investigational New Drug (IND) application of 3D-185 has already been approved by NMPA. Phase 1 clinical trial is on-going in patients with advanced solid tumors who have failed standard treatments to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of 3D-185 monotherapy. Based on the results of Phase 1, we plan to select patients with specific tumor types and clear changes in FGFRs, and further explore the anti-tumor efficacy and safety profile of 3D-185 combined with standard treatment.